home / stock / edit / edit short
Short Information | Editas Medicine Inc. (NASDAQ:EDIT)
Twenty Trading Day Totals | |
---|---|
Total Shorted Volume | 5,164,593 |
Total Actual Volume | 37,486,128 |
Short Trends | |
---|---|
Cover Days | 20 |
Short Days | 0 |
No Change Days | 0 |
Averages | |
---|---|
Average Short Volume | 258,230 |
Average Short Percentage | 13.93% |
Is there a EDIT Short Squeeze or Breakout about to happen?
See the EDIT Short Analysis for free Sign up or Login
Powered by Squeeze Report
Date | Open | Close | High | Low | Total Volume | Short Volume | Short Percentage |
---|---|---|---|---|---|---|---|
05-17-2024 | $5.89 | $5.62 | $5.935 | $5.585 | 1,739,832 | 273,064 | 15.69% |
05-16-2024 | $6.02 | $5.89 | $6.126 | $5.8 | 1,650,447 | 261,943 | 15.87% |
05-15-2024 | $6.09 | $6 | $6.69 | $5.915 | 2,439,478 | 441,646 | 18.1% |
05-14-2024 | $5.86 | $5.68 | $6.18 | $5.67 | 1,599,020 | 225,010 | 14.07% |
05-13-2024 | $5.43 | $5.71 | $6.04 | $5.4 | 1,925,180 | 200,496 | 10.41% |
05-10-2024 | $5.52 | $5.32 | $5.69 | $5.25 | 1,637,650 | 249,446 | 15.23% |
05-09-2024 | $5.19 | $5.56 | $5.76 | $5.1599 | 2,718,539 | 315,767 | 11.62% |
05-08-2024 | $5.4 | $5.035 | $5.4 | $4.91 | 4,252,426 | 543,047 | 12.77% |
05-07-2024 | $5.7 | $5.68 | $5.81 | $5.595 | 1,567,154 | 225,860 | 14.41% |
05-06-2024 | $5.73 | $5.66 | $5.78 | $5.55 | 1,489,925 | 235,786 | 15.83% |
05-03-2024 | $5.8 | $5.67 | $5.97 | $5.64 | 1,613,699 | 251,963 | 15.61% |
05-02-2024 | $5.54 | $5.62 | $5.64 | $5.41 | 1,664,383 | 249,498 | 14.99% |
05-01-2024 | $5.21 | $5.47 | $5.67 | $5.21 | 2,613,818 | 293,354 | 11.22% |
04-30-2024 | $5.33 | $5.21 | $5.36 | $5.2 | 1,467,552 | 187,765 | 12.79% |
04-29-2024 | $5.38 | $5.37 | $5.545 | $5.3 | 1,266,095 | 205,106 | 16.2% |
04-26-2024 | $5.25 | $5.32 | $5.395 | $5.1299 | 1,352,190 | 167,524 | 12.39% |
04-25-2024 | $5.27 | $5.22 | $5.27 | $5.11 | 1,543,788 | 191,972 | 12.44% |
04-24-2024 | $5.51 | $5.35 | $5.59 | $5.28 | 1,563,230 | 151,748 | 9.71% |
04-23-2024 | $5.66 | $5.46 | $5.92 | $5.46 | 1,636,584 | 265,638 | 16.23% |
04-22-2024 | $5.59 | $5.6 | $5.79 | $5.38 | 1,745,138 | 227,960 | 13.06% |
News, Short Squeeze, Breakout and More Instantly...
CAMBRIDGE, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a clinical-stage gene editing company, today announced ...
CAMBRIDGE, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage gene editing company, today announced that two abstracts, including one oral presentation and one poster presentation, detailing clinical data from the RUBY and EdiTHAL trials of renizga...
Research includes the first-ever application of AsCas12a in vivo, optimized LNP delivery, and gene editing RNA guide modifications Data to support...